Pathstone Family Office’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $604K | Buy |
3,082
+360
| +13% | +$70.6K | ﹤0.01% | 949 |
|
|
2023
Q2 | $578K | Buy |
2,722
+902
| +50% | +$192K | 0.01% | 694 |
|
|
2023
Q1 | $385K | Sell |
1,820
-3,512
| -66% | -$742K | 0.01% | 801 |
|
|
2022
Q4 | $891K | Buy |
5,332
+147
| +3% | +$24.6K | 0.01% | 841 |
|
|
2022
Q3 | $1.02M | Buy |
+5,185
| New | +$1.02M | 0.01% | 722 |
|
|
2021
Q3 | – | Sell |
-638
| Closed | -$236K | – | 857 |
|
|
2021
Q2 | $236K | Buy |
+638
| New | +$236K | 0.01% | 718 |
|
|
2021
Q1 | – | Sell |
-2
| Closed | – | – | 791 |
|
|
2020
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 1162 |
|
|
2020
Q3 | $0 | Sell |
2
-2
| -50% | – | ﹤0.01% | 833 |
|
|
2020
Q2 | $0 | Buy |
+4
| New | – | ﹤0.01% | 763 |
|
|
2018
Q2 | – | Sell |
-15
| Closed | -$1K | – | 196 |
|
|
2018
Q1 | $1K | Buy |
+15
| New | +$1K | ﹤0.01% | 343 |
|
|
2017
Q2 | – | Sell |
-12
| Closed | -$1K | – | 440 |
|
|
2017
Q1 | $1K | Buy |
+12
| New | +$1K | ﹤0.01% | 446 |
|